BASKING RIDGE, N.J., Dec. 1 /PRNewswire/ -- Regado Biosciences, Inc., announced today David J. Mazzo, Ph.D., President and Chief Executive Officer, will present at the 20th Annual Piper Jaffray Health Care Conference in New York, NY, on Tuesday, December 2, 2008, at 10:10am (Eastern Standard Time). Dr. Mazzo will discuss the Company's development pipeline, in addition to reviewing recent business and clinical developments.
About Regado Biosciences
Regado Biosciences is pioneering a new therapeutic field with the creation and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect. Enhanced control and flexibility allow physicians to meet the individual needs of patients independent of the setting. Regado is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.
Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.
|SOURCE Regado Biosciences|
Copyright©2008 PR Newswire.
All rights reserved